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Presence of tumour cells shown by immunocytochemical detec-
tion in bone marrow has been convincingly correlated with a
decline in disease-free interval and prognosis (Diel et al, 1996;
Pantel et al, 1996). Specifically, antibodies against cytokeratins
(CK), a family of cytoskeletal proteins expressed in epithelial
cells, have been used successfully in various cancers. As an alter-
native, tumour cells may be detected at extremely low frequencies
using high sensitivity reverse transcription polymerase chain reac-
tion (RT-PCR) assays. While some haematological malignancies
and non-epithelial tumours can be detected using RT-PCR of
tumour-specific translocational gene fusions (Downing et al, 1993,
1995; Hiraga et al, 1998), the detection of epithelium-derived
cancer cells is primarily based on the amplification of either
tissue-specific mRNA expression, e.g. tyrosinase or prostate-
specific antigen (PSA) (Gomella et al, 1997; Ghossein et al, 1998),
or lineage-specific mRNAs like the cytokeratins that characterize
cells of epithelial origin. Assays designed for the detection of
epithelial cells mainly use mRNA of the cytokeratins 18, 19 and
20 (Kruger et al, 1996; Tschentscher et al, 1997; Futamura et al,
1998; Wyld et al, 1998).
The detection of micrometastasis by cytokeratin RT-PCR is
difficult for a number of reasons: cytokeratin 18 (CK18) and
cytokeratin 19 (CK19) are expressed in a variety of epithelia of
different origins (Moll et al, 1982) and expression of their respec-
tive mRNAs has been reported in non-epithelial cells (Traweek
et al, 1993). Furthermore, due to the existence of processed CK
pseudogenes in the human genome, specific amplification may
originate from residual nuclear DNA in sample preparations
(Neumaier et al, 1995; Tschentscher et al, 1997). In contrast, the
expression of CK20 is more restricted and no processed pseudo-
genes have been found (Moll et al, 1993).
In a number of clinical CK20 RT-PCR studies, comparable
diagnostic specificities have been achieved for conventional
(Burchill et al, 1995), nested RT-PCR (Soeth et al, 1996) and
even double-nested RT-PCR (Funaki et al, 1998) systems. Recent
studies have assigned clinical significance and prognostic value to
the detection of CK20 mRNA-positive cells in bone marrow and
peripheral blood samples of breast, gastric, pancreatic and
colorectal cancer patients (Soeth et al, 1996, 1997; Bostick et al,
1998; Weitz et al, 1998). Initiated by our interest in influential
factors in RT-PCR diagnostics (Jung et al, 1997a, 1998) and the
observation of positive RT-PCR results from normal specimens,
we have, in this study, systematically investigated the occurrence
of illegitimate transcription of CK20 mRNA and its influence on
the specificity of RT-PCR assays.
MATERIALS AND METHODS
Specimens
EDTA-blood samples were obtained from healthy volunteers (HD)
and from intensive care unit (ICU) patients with no evidence of
malignant disease. To avoid contamination with skin epithelial
cells, second draws were used in the HD group and skin incisions
were performed before marrow aspiration (CID group). In the ICU
group, the samples were obtained from patients using an arterial
catheter. The ICU-samples were processed using two different
protocols. Of the whole blood specimens, 1 ml was immediately
stabilized in 5 ml 6 M guanidiniumisothiocyanate (GIT), and 1 ml
of the same sample was used for Ficoll plaque density gradient
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centrifugation according to the manufacturer’s instructions
(Amersham-Pharmacia, Freiburg, Germany). The upper layer
containing the mononucleated cells was lysed in 6 M GIT-solution
prior to RNA purification.
One sample (5 ml) of a healthy donor was processed in the same
way as the patients’ specimens described above. Additionally the
layer containing the polymorphonuclear (granulocyte) fraction
was further processed by osmotic erythrocyte lysis and subsequent
wash steps to remove inhibitory haemoglobin from the cell frac-
tion prior to CK20 RT-PCR amplification.
Granulocytes count
Granulocytes were differentiated and counted using VCS-tech-
nology with a routine Coulter-analyser.
RNA purification
Total RNA was purified from all specimens using the standard
acid phenol–chloroform extraction method (Chomczynski and
Sacchi, 1987). Nucleic acid concentrations were verified by spec-
trophotometry at 260 nm and 280 nm wavelengths, and approxi-
mately 2 mg total RNA were used for subsequent analysis as
described previously (Gerhard et al, 1994). mRNA integrity was
checked by b2-microglobulin RT-PCR as described previously
(Jung et al, 1997b).
RT-PCR assay
CK20 RT-PCR assays were performed as published (Soeth et al,
1996). Each sample was investigated twice and scored positive, if
at least in one assay a specific amplification occurred. Positive
samples were re-examined in RT-PCR-reactions without reverse
transcriptase to exclude: (i) contamination with PCR-products
or (ii) amplification of processed pseudogene sequences from
contaminating nuclear DNA. The analytical sensitivity of the
assay was assessed by limiting dilutions of HT 29 cells in 106
Chinese hamster ovary cells (CHO). For the sensitivity limit in this
study of ten HT29 cells in 106 CHO-cells a 100% reproducibility
was reached. In contrast to human blood leucocytes, CHO cells do
not express CK20-like sequences to interfere with the HT29 signal
and are therefore suitable for the dilution experiment.
Statistical analysis
Statistical significance was calculated using the two-tailed
unpaired  t-test. Values are means with standard error.
RESULTS AND DISCUSSION
A total of 67 specimens from healthy donors (HD; n = 33), patients
suffering from inflammatory disease (CID; n = 14) and patients
from an intensive care unit (ICU; n = 20) were investigated in this
study using an assay designed to amplify CK20 mRNA. In the
originally investigated stabilized lysates from bone marrow of
CID patients (n = 14) and peripheral blood of HD (n = 33) we had
encountered positive results in 35% and 24% respectively. This
represents a markedly lower diagnostic specificity than has been
previously reported for CK20 detection by RT-PCR (Burchill et al,
1995; Soeth et al, 1997; Funaki et al, 1998). To verify these results
we investigated the interference of mRNA from nucleated blood
cells on the CK20 RT-PCR specificity in a panel of peripheral
blood samples from ICU patients with non-malignant conditions
(Table 1). In addition to the blood lysate preparation, the speci-
mens were subjected to a standard Ficoll-plaque density gradient
separation of the mononuclear and granulocyte cell fraction.
While 24% of the blood lysates from the HD group were found
positive, the diagnostic unspecificity observed in the bone marrow
lysates (35%) was very similar to that found in the peripheral
blood lysates obtained from the ICU patient group (40%; Table 1).
Table 1
No.      Diagnosis Serum CRP Granulocytes Lysed whole Lysed mononuclear
(mg l–1) (mg ml–1) blood cells
1 Cardiac arrest 129 10.3 pos./pos. neg./neg.
2 Diabetes mellitus 342 7.7 pos./pos. neg./neg.
3 Pancreatitis 122 11.2 neg./pos. neg./neg.
4 Coronary artery disease 125 6.4 neg./neg. neg./neg.
5 Pneumonia 248 19.6 neg./pos. neg./neg.
6 Pneumonia 168 13.6 neg./neg. neg./neg.
7 Pulmonary embolism 300 10.9 neg./neg. neg./neg.
8 Septicaemia 107 10.2 neg./neg. neg./neg.
9 Myocardial infarction 22 19.4 pos./pos. neg./neg.
10 Septic inflammation 28 4.3 neg./neg. neg./neg.
11 Pneumonia 139 6.3 neg./neg. neg./neg.
12 Coronary artery disease 61 7.1 pos./pos. neg./neg.
13 Peritonitis 148 6.7 neg./neg. neg./neg.
14 Drug intoxication 32 6.1 neg./neg. neg./neg.
15 Pancreatitis 87 4.6 neg./neg. neg./neg.
16 Ulcerative colitis 21 3.7 neg./neg. neg./neg.
17 Pneumonia 82 6.5 neg./neg. neg./neg.
18 Aspiration pneumonia 146 2.3 neg./neg. neg./neg.
19 Pneumonia, hepatitis 158 11.9 pos./pos. neg./neg.
20 Intoxication, pneumonia 10 10.1 pos./pos. neg./neg.
CK20 mRNA positivity rate (%) 40% 0%
neg, negative; pos, positive.872 R Jung et al
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Among the samples found positive by duplicate testing, 3 and 5
showed specific amplification products in one or both tests respec-
tively. This variability is explained by stochastic effects at the limit
of analytical sensitivity as has been discussed in detail by Jung
et al (1997).
The positivity rate in the ICU patients whole blood lysates
correlated with the number of granulocytes in the sample.
Specifically, the mean granulocyte count per microlitre was
significantly higher in the group of CK20-positive ICU-patients
compared to the group of CK20-negative ICU-patients (12.3 ± 4.8
vs 6.8 ± 3.1 granulocytes ml–1; P < 0.02; Table 2). The diagnostic
specificity of the CK20 RT-PCR test was completely restored,
when the specimen was subjected to Ficoll-plaque centrifugation
prior to further analysis. Ficoll density gradient centrifugation
separates two main white blood cell subpopulations: (i) lympho-
and monocytes in the upper layer, and (ii) granulocytes above and
in the red blood cell fraction. As shown in Figure-1, RT-PCR
assays performed on the fraction of mononucleated cells were
negative. In contrast, the CK20-expressing cells were positively
identified in the granulocyte fraction of blood leucocytes pre-
viously depleted of erythrocytes by osmotic lysis.
The frequency of positive CK20 results was found to correlate
significantly with the granulocyte count (P < 0.02). This is
consistent with the observation that HD showed 24% positive
samples, while 40% positives were found in the ICU patient group.
This background mRNA expression in non-cancer patients and
healthy individuals appears to be different from the illegitimate
transcription occasionally found for other mRNA targets. We have
recently shown in vitro that leucocytes can be induced by
cytokines and growth factors to express mRNA targets used for the
detection of circulating cancer cells. For example, the mRNA
expression of the human carcinoembryonic antigen (CEA) is
specifically inducible by interferon-g, but not by interleukin 
(IL)-3, IL-6, granulocyte colony-stimulating factor, granulocyte–
macrophage colony-stimulating factor or SCF. On the other hand,
an induction of CK19 mRNA expression can be observed after
7 days of tissue culture without the addition of any of these
cytokines (Jung et al, 1998). In contrast, none of the cytokines
used was able to induce CK20 mRNA expression in this system
(data not shown). Together with the correlation to the granulocyte
count in the sample, this suggests a low abundance constitutive-
type of CK20 mRNA expression in these cells in the peripheral
blood. This interpretation is further corroborated by the observa-
tion that the positivity in specimens obtained from non-malignant
patients does not correlate with inflammatory reactions or acute
phase markers as judged by serum concentrations of the C-reactive
protein (Table 2).
Our results demonstrate for the first time that CK20 mRNA
expression is not limited to epithelial cells, but also occur in
normal granulocytes. The data also suggest that CK20 mRNA is
stably expressed at low levels in these cells rather than modulated
under conditions of clinical illness. Studies using quantitative
CK20 RT-PCR have to be performed to answer this question
conclusively. However, these results allow the delineation of
rational CK20 RT-PCR assay designs with respect to the clinical
materials used, i.e. peripheral blood, bone marrow or other bodily
fluids. Firstly, assays based on enriched mononucleated cells as
sample material require no knowledge of the granulocyte count.
On the other hand, disadvantages of the frequently-used Ficoll
density gradient separation include the potential loss of malignant
cells and difficulty to standardize the procedure. Secondly, for
assays using lysates of whole blood or bone marrow as a mRNA,
the number of granulocytes has to be determined. For those assays,
cut-off values can be readily defined based on leucocyte counts. In
contrast to mRNA targets that are subject to transcriptional modu-
lation under different clinical conditions, the use of CK20 mRNA
may provide a significant diagnostic advantage. Studies are now
underway to establish, in a quantitative format, the cut-off values
to improve the diagnostic specificity in the detection of minimal
residual disease in CK20-positive human cancers.
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